Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study
doctors think that giving medicines to affect the immune system soon after diabetes is
diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better
glucose control.
Researchers believe that tocilizumab could have some effect on the cells in the immune system
that are thought to be involved in the development of type 1 diabetes. This study will test
whether tocilizumab can help preserve or delay destruction of remaining beta cells in people
recently diagnosed type 1 diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Immune Tolerance Network (ITN) PPD Rho Federal Systems Division, Inc.